Record-Breaking Price Movement
On 11 December 2025, Shukra Pharmaceuticals touched an intraday peak of Rs.48.76, representing a 5.00% gain on the day. The stock opened at this level and maintained the price throughout the trading session, reflecting strong demand and market confidence. This price point is the highest recorded in the stock’s history, underscoring a remarkable phase of growth.
The stock’s performance today notably outpaced the broader sector, outperforming by 5.11%. This outperformance is particularly significant given the Pharmaceuticals & Biotechnology sector’s typically steady but competitive nature.
Consistent Gains Over Multiple Sessions
Shukra Pharmaceuticals has demonstrated a consistent upward trend, registering gains for six consecutive trading days. Over this period, the stock has delivered returns of 27.11%, a substantial appreciation that signals sustained investor interest and positive market dynamics.
Such a streak of consecutive gains is indicative of strong momentum and resilience, especially in a sector where regulatory and market factors can often introduce volatility.
Technical Indicators Support Strength
From a technical perspective, Shukra Pharmaceuticals is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment across multiple timeframes suggests a solid foundation for the current price levels and reflects a broad-based strength in the stock’s price action.
The gap-up opening by 5% today further emphasises the bullish sentiment prevailing among market participants.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Long-Term Performance Context
Examining Shukra Pharmaceuticals’ performance over extended periods reveals extraordinary growth relative to the benchmark Sensex. Over the past year, the stock has recorded a return of 605.64%, while the Sensex has shown a comparatively modest 3.69% increase. Year-to-date figures show a 257.56% rise for the stock against an 8.18% gain for the Sensex.
Over three years, Shukra Pharmaceuticals’ returns stand at an impressive 5911.81%, dwarfing the Sensex’s 35.94% growth. The five-year and ten-year returns further illustrate this trend, with the stock appreciating by 21,999.96% and 15,031.34% respectively, compared to the Sensex’s 83.37% and 237.53% over the same periods.
This long-term outperformance highlights the company’s ability to generate substantial value over time within the Pharmaceuticals & Biotechnology sector.
Comparative Short-Term Performance
In shorter timeframes, Shukra Pharmaceuticals continues to demonstrate strength. The one-week return of 23.16% contrasts with the Sensex’s decline of 0.86%, while the one-month return of 19.04% exceeds the Sensex’s 0.79% gain. The three-month performance is particularly notable, with the stock rising 75.52% compared to the Sensex’s 3.66%.
These figures underscore the stock’s ability to maintain momentum across various market cycles and time horizons.
Considering Shukra Pharmaceuticals ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Market Capitalisation and Sector Positioning
Shukra Pharmaceuticals operates within the Pharmaceuticals & Biotechnology industry and sector, which is characterised by innovation, regulatory oversight, and evolving market demands. The company’s market capitalisation grade stands at 4, reflecting its established presence and scale within the sector.
The stock’s recent price action and all-time high achievement reinforce its position as a noteworthy player in this competitive industry landscape.
Summary of Recent Market Activity
Today’s 5.00% gain and the stock’s ability to open at its highest level of Rs.48.76 without retreating during the session indicate a strong market consensus on its valuation. The outperformance relative to the Sensex’s 0.17% gain further highlights its relative strength on the trading day.
Such market behaviour often reflects a combination of company-specific factors and broader sectoral trends that favour the stock’s valuation.
Conclusion
Shukra Pharmaceuticals’ ascent to an all-time high of Rs.48.76 marks a significant milestone in its market journey. Supported by consistent gains over multiple sessions, strong technical indicators, and exceptional long-term returns relative to the Sensex, the stock’s performance exemplifies robust market dynamics within the Pharmaceuticals & Biotechnology sector.
While the stock’s recent momentum is notable, its sustained presence above key moving averages and consistent outperformance across various timeframes provide a comprehensive picture of its current market standing.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
